SCHEMBL4783385

SCHEMBL4783385

CS(=O)(=O)N1CCN(c2n[nH]c3ccc([N+](=O)[O-])cc23)CC1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
LMNA P02545 2/20 0.54
MAPT P10636 3/20 0.46
HPGD P15428 1/20 0.46
CNR1 P21554 2/20 0.44
KMT2A Q03164 2/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 1/20 0.43
CNR2 P34972 2/20 0.43
LRRK2 Q5S007 7/20 0.42
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
CSNK2A1 P68400 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4799096 0.90 ALDH1A1 (0.46) ALDH1A1LMNAMAPTHPGDCNR1
SCHEMBL4781802 0.85 MAPT (0.50) ALDH1A1LMNAMAPTHPGDCNR2
SCHEMBL4785656 0.81 LMNA (0.54) ALDH1A1LMNAMAPTHPGDHTT
SCHEMBL2466571 0.81 MAPK1 (0.52) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL4783785 0.81 CNR1 (0.53) CNR1CNR2LRRK2
SCHEMBL4784574 0.76 SIRT6 (0.50) ALDH1A1LMNAMAPTHPGDKMT2A
SCHEMBL30833799 0.76 SIRT6 (0.50) ALDH1A1LMNAMAPTHPGDKMT2A
SCHEMBL4783386 0.74 MAPT (0.41) MAPTHPGDCNR2CSNK2A1
SCHEMBL6152580 0.73 MAPT (0.56) ALDH1A1LMNAMAPTHPGDCNR1
SCHEMBL22445861 0.72 MAPT (0.47) ALDH1A1LMNAMAPTHPGDCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
WO-2008061109-A2 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed
WO-2008061109-A2 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS MCHR1, MCHR2, MC1R ALDH1A1 2090/4885LMNA 4549/4885MAPT 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.